title: Radiation dose as a risk factor for malignant melanoma following childhood cancer.
abstract: The aim of this study was to determine therapy-related risk factors for the development of melanoma after childhood cancer. Among 4401 3-year survivors of a childhood cancer in eight French and British centres and 25120 patients younger than 20 years old at first malignant neoplasm (FMN) extracted from the Nordic Cancer Registries, 16 patients developed a melanoma as a second malignant neoplasm (SMN). A cohort study of the French and British cohorts was performed. In a nested case-control study, the 16 patients who developed a melanoma as a SMN (cases) were matched with 3-5 controls in their respective cohort according to gender, age at the first cancer, the calendar year of occurrence of the first cancer and follow-up. Radiotherapy appeared to increase the risk of melanoma for local doses >15 Gy, Odds Ratio (OR)=13 (95% Confidence Interval (CI): 0.94-174). Regarding chemotherapy, we observed an increased OR for both alkylating agents and spindle inhibitors, OR=2.7 (95% CI: 0.5-14). Children treated for a gonadal tumour as a FMN were found to be at a higher risk of melanoma, OR=8.7 (95% CI: 0.9-86). The adjusted OR for the local radiation dose was 1.07 (95% CI: 1.00-1.15). In conclusion, radiotherapy may contribute to an increased risk of melanoma as a SMN, but only at very high doses of low linear energy transfer radiation. Common genetic origins between gonadal tumours and malignant melanomas are likely.
authors.affiliation: National Institute of Public Health and Medical Research (INSERM XR521), IGR, 39 rue Camille Desmoulins, 94805 cedex, Villejuif, France.
authors.forename: S
authors.initials: S
authors.lastname: Guérin
authors.forename: A
authors.initials: A
authors.lastname: Dupuy
authors.forename: H
authors.initials: H
authors.lastname: Anderson
authors.forename: A
authors.initials: A
authors.lastname: Shamsaldin
authors.forename: G
authors.initials: G
authors.lastname: Svahn-Tapper
authors.forename: T
authors.initials: T
authors.lastname: Moller
authors.forename: E
authors.initials: E
authors.lastname: Quiniou
authors.forename: S
authors.initials: S
authors.lastname: Garwicz
authors.forename: M
authors.initials: M
authors.lastname: Hawkins
authors.forename: M F
authors.initials: MF
authors.lastname: Avril
authors.forename: O
authors.initials: O
authors.lastname: Oberlin
authors.forename: J
authors.initials: J
authors.lastname: Chavaudra
authors.forename: F
authors.initials: F
authors.lastname: de Vathaire
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008545:Melanoma / Q000209:etiology; D008875:Middle Aged; D009369:Neoplasms / Q000532:radiotherapy*; D009381:Neoplasms, Radiation-Induced / Q000209:etiology*; D016609:Neoplasms, Second Primary / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D012307:Risk Factors; D012878:Skin Neoplasms / Q000209:etiology; D017741:Survivors